EIDX - RM LAW Announces an Investigation of Eidos Therapeutics Inc.

BERWYN, Pa., April 5, 2019 /PRNewswire/ -- RM LAW, P.C. announces an investigation on behalf of Eidos Therapeutics, Inc. (NASDAQ: EIDX) ("Eidos Therapeutics" or the "Company") investors concerning the Company and its officers' possible violations of federal securities laws.

If you purchased shares of Eidos Therapeutics and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.

On April 1, 2019, after the market closed, Eidos Therapeutics filed a Form 8-K with the SEC announcing that its previously issued financial statements for the first three quarterly periods in the year ended December 31, 2018 could no longer be relied upon.

For more information regarding this, please contact RM LAW, P.C.  (Richard A. Maniskas, Esquire) toll-free at (844) 291-9299 or by email at rm@maniskas.com or click here. For more information about class action cases in general or to learn more about RM LAW, P.C. please visit our website by clicking here. 

RM LAW, P.C. is a national shareholder litigation firm. RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

SOURCE RM LAW, P.C.